Medtronic

Q4 FY2026 EarningsFY26 revenue reached $36.4B, up 8.43% YoY, driven by double-digit growth in Cardiovascular (11.98%) and Diabetes (12.96%). GAAP net income was $4.8B, up 2.98% YoY, while non-GAAP diluted EPS rose 0.73% to $5.53. Gross margin faced pressure from $185M in increased tariffs, and the effective tax rate rose to 21.2% due to Pillar Two global minimum tax and the MiniMed separation.